Table 4

Summary of the characteristics of studies that compare TUNA with other therapies

Author [reference number]


Bruskewitz [50]

Roehrborn [51]

Chandrasekar [52]

Cimentepe [53]

Hill [54]

Schatzl [55,57]

Arai [56]

Minardi [58]


Design

RCT

RCT

RCT

RCT

RCT

Prospective cohort

Prospective cohort

Prospective cohort

No. patients

121

121

156

59

121

95

204

212

TUNA [N. patients]

65

65

76

26

65

15

51

24

Comparator [No. Patients]

TURP [56]

TURP [56]

TURP [76]

TURP [33]

TURP [56]

TURP [28]

TUVP [17]

VLAP [15]

HIFU [20]

TURP [65]

TUMT [40]

ILC[48]

TURP [90]

TUVP [13]

ILC[71]

WIT [13]

Duration of symptoms

> 3months

> 3months

Not reported

Not reported

> 3months

Not reported

Not reported

Not reported

Anesthesia

TUNA: Local

TURP: General

TUNA: Local

TURP: General

Not reported

Regional

TUNA: Local

TURP: General

General/Regional

TUNA, ILC: Not reported

TURP: Spinal

TUMT: Local

TUNA-WIT:Local

TUVP, ILC: Spinal

TURP: General

Variables assessed

Symptom, QoL, Qmax, PVR, prostatic size, adverse effects duration of procedure, hospital stay

Pdetat Qmax No. Abrams-Griffiths

Symptom, QoL, Qmax, adverse effects, hospital stay, re-treatment

Symptom, QoL, Qmax, PVR, sexual function, prostatic size, adverse effects, duration of procedure, hospital stay, re-treatment

Symptom, QoL, Qmax, PVR, adverse effects, hospital stay, re-treatment

Symptom, QoL, Qmax, PVR, adverse effects, hospital stay, re-treatment

Symptom, QoL, Qmax, PVR, sexual function, adverse effects.

Symptom, QoL, Qmax, PVR, Pdet at Qmax, prostatic size, adverse effects, duration, re-treatment

Follow-up

12 months

6 months

7 years

18 months

5 years

6 weeks/24 m

3 months

24 months

Randomization method specified

Yes

Yes

No

No

Not applicable

Not applicable

Not applicable

Inclusion/exclusion criteria specified

Yes

Yes

No

Yes

Yes

Yes

Yes

Concomitant treatment specified

Yes

Yes

No

Yes

Yes

No

No

Intention-to-treat analysis

Yes

Yes

Not reported

Not reported

Yes

Not reported

Not reported

Blind/Independent evaluation

Not reported

Not reported

Not reported

Not reported

Not reported

Not reported

Not reported

Losses

TUNA:9%

TURP:16%

None

Not reported

None

TUNA>72%

TURP > 60%

TUVP [4]

VLAP [4]

HIFU [4]

TUNA [3]

TUNA [9]

TURP [10]

TUMT [6],

ILC [6]

Not reported


Abbreviations: RCT: Randomized controlled trial. TUNA (Transurethral Needle Ablation). TURP (Transurethral resection). TUMT (Transurethral Microwave Thermotherapy). WIT (Water-induced Thermotherapy). ILC (Interstitial Laser Coagulation). TUVP (Transurethral Electrovaporization of the Prostate). VLAP (Visual Laser Ablation of the Prostate). HIFU (Transrectal High Intensity Focused Ultrasound). QoL: Quality of life score. Qmax: Maximum urinary flow rate. PVR: Post-void residual volume. Pdet at Qmax: Detrusor presures at peak flow rate.

Bouza et al. BMC Urology 2006 6:14   doi:10.1186/1471-2490-6-14

Open Data